Key result
The POLARx cryoballoon system achieved 100% acute pulmonary vein isolation, similar to the Arctic Front Advance system, but with longer procedure times (113.3 vs 100.9 min; p<0.001).
Why the study?
A novel cryoballoon single-shot device was recently designed, motivating a comparison of its efficacy, safety, and characteristics with the established system.
Does the POLARx cryoballoon system improve procedural efficacy and safety compared to the Arctic Front Advance system in patients undergoing pulmonary vein isolation for atrial fibrillation?
Population
596 patients undergoing cryoballoon-guided ablation for AF
Comparison
POLARx vs Arctic Front Advance (Pro)
Design
Cohort study
Authors
Loading...
Supports POLARx as viable alternative for acute PVI; extends device comparisons while highlighting efficiency trade-offs.
Cohort (n=596)
Does the POLARx cryoballoon system improve procedural efficacy and safety compared to the Arctic Front Advance system in patients undergoing pulmonary vein isolation for atrial fibrillation?
Absolute Event Rate: 100% vs 100%
The novel POLARx cryoballoon system is as safe and effective for acute PVI as the established AFA system, though it is associated with longer procedure and fluoroscopy times.
Guckel et al. (2022) conducted a cohort in Atrial fibrillation (n=596). POLARx cryoballoon system vs. Arctic Front Advance (AFA) cryoballoon system was evaluated on Acute pulmonary vein isolation (PVI). The POLARx cryoballoon system achieved 100% acute pulmonary vein isolation, similar to the Arctic Front Advance system, but with longer procedure times (113.3 vs 100.9 min; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: